Clinicopathological Predictive Factors of Melanoma Lung Metastases
- *Corresponding Author:
- Paolino G
La Sapienza University of Rome
Viale del Policlinico 15, 00186 Rome, Italy
Tel: +39 349 8465167
Fax: +39 06 4462104
E-mail: [email protected]
Received date: May 12, 2014; Accepted date: June 2, 2014; Published date: June 12, 2014
Citation: Paolino G, Bottoni U, Clerico R, Didona D, Venuta F, et al. (2014) Clinicopathological Predictive Factors of Melanoma Lung Metastases. J Integr Oncol 3:119. doi:10.4172/2329-6771.1000119
Copyright: © 2014 Paolino G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: The lung is the second most common site for metastatic malignant melanoma, with a poor prognosis. In this regard, identify clinicopathological predictors for Melanoma Lung Metastases (MLM) plays a pivotal role in clinical practice.
Methods: We computer-searched the clinical records of all our patients registered in our melanoma database to identify patients that presented MLM. Kaplan-Meier product was used to estimate time to MELANOMA LUNG METASTASES (TMLM) and Overall Survival (OS); while the log-rank test was used to evaluate differences between the survival curves. Cox proportional hazards regression was performed in the analysis between clinicopathological features of the primary tumor and MLM.
Results: A total of 63 patients with MLM were included in our analysis. Median TMLM was 27.4 months, while median OS was 55.5 months, with a Median Lung Metastases Survival (MLMS) of 10 months. Melanoma patients with a primary axial tumor (p<0.001) and with an age ≤ 60 years (p=0.01) showed a better TMLM. While OS was statistically significant higher only in axial melanomas (p<0.001), multivariate analysis showed that peripheral site of the primary tumor remained the main predictor to develop MLM, with a significant influence in TMLM and also in the long-term (p<0.01 and p=0.04).
Conclusions: Currently no standardized therapies exist for MLM. In this regard, the prevention of secondary recurrences plays a pivotal role in the management of melanoma patients. According to our results, peripheral melanoma is the main predictor for development of MLM.